{"id":16118,"date":"2012-04-06T15:53:28","date_gmt":"2012-04-06T19:53:28","guid":{"rendered":"http:\/\/www.iposgoode.ca\/?p=16118"},"modified":"2012-04-06T15:53:28","modified_gmt":"2012-04-06T19:53:28","slug":"should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so","status":"publish","type":"post","link":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/","title":{"rendered":"Should Canada Strengthen IP Protection for Pharmaceutical Products?  The European Union Thinks So..."},"content":{"rendered":"<p>The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (<a href=\"http:\/\/www.international.gc.ca\/trade-agreements-accords-commerciaux\/agr-acc\/eu-ue\/can-eu.aspx?view=d\">CETA<\/a>).\u00a0 A key issue has been ensuring that Canadian intellectual property rights for pharmaceutical products are brought in line with EU standards.\u00a0 It appears that the EU believes Canada\u2019s legal regime regulating the approval of drugs does not provide intellectual property rights holders with adequate protection.<\/p>\n<p><!--more--><\/p>\n<p>Canada\u2019s current drug approval system is administered under the <a href=\"http:\/\/laws-lois.justice.gc.ca\/eng\/regulations\/SOR-93-133\/index.html\">Patented Medicines Notice of Compliance (PM(NOC)) Regulations<\/a>.\u00a0 Under this system a pharmaceutical company must obtain approval from the Minister of Health in the form of a Notice of Compliance (NOC) before a new drug can be sold in Canada.\u00a0 To obtain a NOC an applicant (typically a research based pharmaceutical company or \u201cinnovator\u201d) must submit a new drug submission (NDS) containing data that establishes the safety and efficacy of the drug.\u00a0 Once a NOC has been issued, the company may list patents related to the drug on the patent register.\u00a0 When a generic drug manufacturer wishes to market a drug it must also obtain a NOC.\u00a0 Where the generic manufacturer can satisfy the Minister of Health that its drug is pharmaceutically equivalent to a drug that has already obtained approval, they may file an abbreviated new drug submission (ANDS) and rely on the safety and efficacy data filed by the innovator in the original NDS.\u00a0 Data within an NDS is covered by a data protection regime that prevents a generic manufacturer from filing an ANDS for 6 years and a NOC being issued for 8 years.\u00a0 In addition to the data protection hurdle, a generic manufacturer must also address the patents listed on the register before a NOC will be granted.\u00a0 The patents can be addressed by convincing the Minister of Health that (1) the patents will not be infringed,\u00a0 (2) the patents are invalid or (3) that it will wait until the patents have expired before going to market.<\/p>\n<p>In order to bolster Canada\u2019s intellectual property rights and harmonize them with European standards, the EU has proposed three changes:<\/p>\n<ol>\n<li>Provide innovator companies with fair treatment under the PM(NOC) Regulations by providing them with the same right of appeal currently afforded to generic manufacturers;<\/li>\n<li>Extend the term of data protection; and<\/li>\n<li>Adopt patent term restoration (PTR), a mechanism that allows a patentee to \u201crecoup\u201d some of the patent term lost during drug development and regulatory approval.<\/li>\n<\/ol>\n<p>The association of Canada\u2019s leading innovator drug companies (<a href=\"https:\/\/www.canadapharma.org\/en\/default.aspx\">Rx&amp;D<\/a>) supports the proposed changes and encourages their adoption by the Canadian government.\u00a0 Rx&amp;D claim that increased intellectual property rights will allow them to invest more money into research and development leading to new drugs for Canadians.\u00a0 Rx&amp;D is not the only group in favour of these proposals.\u00a0Lawyers from Norton Rose published a <a href=\"http:\/\/www.nortonrose.com\/knowledge\/publications\/57553\/ceta-trade-negotiations-2011--drug-market-exclusivity-in-the-eu-and-canada\">report<\/a> addressing why Canada should adopt these changes and strengthen intellectual property protection.\u00a0 The Norton Rose report suggests that drug approval rates in the EU are faster than those in Canada and that by harmonizing Canada\u2019s system with that of the EU, Canadians will have faster access to new drugs.\u00a0 The report also contends that harmonization would not extend the total market exclusivity granted to Canadian drugs in the majority of cases.<\/p>\n<p>Canada\u2019s <a href=\"http:\/\/canadiangenerics.ca\/en\/index.asp\">generic pharmaceutical companies<\/a> oppose the EU\u2019s proposed changes.\u00a0 It is their position that increased intellectual property rights will result in greater market exclusivity for brand name pharmaceuticals, delays in the emergence of cheaper generic drugs and ultimately greater costs to Canada\u2019s health care system.\u00a0 This position is supported by a <a href=\"http:\/\/www.canadiangenerics.ca\/en\/news\/docs\/02.07.11CETAEconomicImpactAssessment-FinalEnglish11.pdf\">study<\/a> demonstrating that if all three proposals are adopted it could cost Ontario taxpayers up to $1.2 billion annually.\u00a0 Furthermore, the <a href=\"http:\/\/www.fin.gov.on.ca\/en\/reformcommission\/chapters\/ch5.html#ch5-q\">Drummond Report recommends<\/a> that provincial governments \u201cwork with the federal government to ensure that Ontario\u2019s interests in expanding use of generic drugs are not undermined by a Canada-European Union Free Trade Agreement.\u201d\u00a0 The report also stated that the drug patent proposals advanced by the EU \u201ccould cost Ontario dearly since generic drugs would be kept off the market for a longer time.\u201d\u00a0\u00a0 Generic pharmaceutical companies also suggest that increased intellectual property rights will not result in greater investment in research and development by innovator companies.<\/p>\n<p>With CETA negotiations set to conclude sometime in 2012, the Canadian government will be forced to make some difficult decisions, given the importance of health care and the tough economic times facing Canadians and Canadian companies alike.<\/p>\n<p>&nbsp;<\/p>\n<p><em>Sean Jackson is a J.D. candidate at Osgoode Hall Law School.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (CETA).\u00a0 A key issue has been ensuring that Canadian intellectual property rights for pharmaceutical products are brought in line with EU standards.\u00a0 It appears that the EU believes Canada\u2019s legal regime regulating the approval of drugs does not provide [&hellip;]<\/p>\n","protected":false},"author":2140,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","footnotes":""},"categories":[1014,1086,1013,60,10,184],"tags":[1032],"class_list":["post-16118","post","type-post","status-publish","format-standard","hentry","category-access-to-medicines","category-european-union","category-feature-post","category-ip","category-patents","category-pharmaceutical-drugs","tag-sean-jackson"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So... - IPOsgoode<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So... - IPOsgoode\" \/>\n<meta property=\"og:description\" content=\"The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (CETA).\u00a0 A key issue has been ensuring that Canadian intellectual property rights for pharmaceutical products are brought in line with EU standards.\u00a0 It appears that the EU believes Canada\u2019s legal regime regulating the approval of drugs does not provide [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/\" \/>\n<meta property=\"og:site_name\" content=\"IPOsgoode\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-06T19:53:28+00:00\" \/>\n<meta name=\"author\" content=\"ccraig\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ccraig\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/\"},\"author\":{\"name\":\"ccraig\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#\\\/schema\\\/person\\\/09b0ef7189d5a2bd6fef2472e5ea5b94\"},\"headline\":\"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So...\",\"datePublished\":\"2012-04-06T19:53:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/\"},\"wordCount\":761,\"keywords\":[\"sean jackson\"],\"articleSection\":[\"Access to Medicines\",\"European Union\",\"Feature Post\",\"IP\",\"Patents\",\"Pharmaceutical Drugs\"],\"inLanguage\":\"en-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/\",\"url\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/\",\"name\":\"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So... - IPOsgoode\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#website\"},\"datePublished\":\"2012-04-06T19:53:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#\\\/schema\\\/person\\\/09b0ef7189d5a2bd6fef2472e5ea5b94\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/06\\\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So...\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#website\",\"url\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/\",\"name\":\"IPOsgoode\",\"description\":\"An Authoritive Leader in IP\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#\\\/schema\\\/person\\\/09b0ef7189d5a2bd6fef2472e5ea5b94\",\"name\":\"ccraig\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g\",\"caption\":\"ccraig\"},\"url\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/author\\\/ccraig\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So... - IPOsgoode","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/","og_locale":"en_US","og_type":"article","og_title":"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So... - IPOsgoode","og_description":"The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (CETA).\u00a0 A key issue has been ensuring that Canadian intellectual property rights for pharmaceutical products are brought in line with EU standards.\u00a0 It appears that the EU believes Canada\u2019s legal regime regulating the approval of drugs does not provide [&hellip;]","og_url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/","og_site_name":"IPOsgoode","article_published_time":"2012-04-06T19:53:28+00:00","author":"ccraig","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ccraig","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/#article","isPartOf":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/"},"author":{"name":"ccraig","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#\/schema\/person\/09b0ef7189d5a2bd6fef2472e5ea5b94"},"headline":"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So...","datePublished":"2012-04-06T19:53:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/"},"wordCount":761,"keywords":["sean jackson"],"articleSection":["Access to Medicines","European Union","Feature Post","IP","Patents","Pharmaceutical Drugs"],"inLanguage":"en-CA"},{"@type":"WebPage","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/","url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/","name":"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So... - IPOsgoode","isPartOf":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#website"},"datePublished":"2012-04-06T19:53:28+00:00","author":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#\/schema\/person\/09b0ef7189d5a2bd6fef2472e5ea5b94"},"breadcrumb":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/06\/should-canada-strengthen-ip-protection-for-pharmaceutical-products-the-european-union-thinks-so\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/"},{"@type":"ListItem","position":2,"name":"Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So..."}]},{"@type":"WebSite","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#website","url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/","name":"IPOsgoode","description":"An Authoritive Leader in IP","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Person","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#\/schema\/person\/09b0ef7189d5a2bd6fef2472e5ea5b94","name":"ccraig","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g","caption":"ccraig"},"url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/author\/ccraig\/"}]}},"taxonomy_info":{"category":[{"value":1014,"label":"Access to Medicines"},{"value":1086,"label":"European Union"},{"value":1013,"label":"Feature Post"},{"value":60,"label":"IP"},{"value":10,"label":"Patents"},{"value":184,"label":"Pharmaceutical Drugs"}],"post_tag":[{"value":1032,"label":"sean jackson"}]},"featured_image_src_large":false,"author_info":{"display_name":"ccraig","author_link":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/author\/ccraig\/"},"comment_info":"","category_info":[{"term_id":1014,"name":"Access to Medicines","slug":"access-to-medicines","term_group":0,"term_taxonomy_id":1014,"taxonomy":"category","description":"","parent":0,"count":34,"filter":"raw","cat_ID":1014,"category_count":34,"category_description":"","cat_name":"Access to Medicines","category_nicename":"access-to-medicines","category_parent":0},{"term_id":1086,"name":"European Union","slug":"european-union","term_group":0,"term_taxonomy_id":1086,"taxonomy":"category","description":"","parent":0,"count":93,"filter":"raw","cat_ID":1086,"category_count":93,"category_description":"","cat_name":"European Union","category_nicename":"european-union","category_parent":0},{"term_id":1013,"name":"Feature Post","slug":"feature-post","term_group":0,"term_taxonomy_id":1013,"taxonomy":"category","description":"","parent":0,"count":296,"filter":"raw","cat_ID":1013,"category_count":296,"category_description":"","cat_name":"Feature Post","category_nicename":"feature-post","category_parent":0},{"term_id":60,"name":"IP","slug":"ip","term_group":0,"term_taxonomy_id":60,"taxonomy":"category","description":"","parent":0,"count":1229,"filter":"raw","cat_ID":60,"category_count":1229,"category_description":"","cat_name":"IP","category_nicename":"ip","category_parent":0},{"term_id":10,"name":"Patents","slug":"patents","term_group":0,"term_taxonomy_id":10,"taxonomy":"category","description":"","parent":0,"count":557,"filter":"raw","cat_ID":10,"category_count":557,"category_description":"","cat_name":"Patents","category_nicename":"patents","category_parent":0},{"term_id":184,"name":"Pharmaceutical Drugs","slug":"pharmaceutical-drugs","term_group":0,"term_taxonomy_id":184,"taxonomy":"category","description":"","parent":0,"count":112,"filter":"raw","cat_ID":184,"category_count":112,"category_description":"","cat_name":"Pharmaceutical Drugs","category_nicename":"pharmaceutical-drugs","category_parent":0}],"tag_info":[{"term_id":1032,"name":"sean jackson","slug":"sean-jackson","term_group":0,"term_taxonomy_id":1032,"taxonomy":"post_tag","description":"","parent":0,"count":8,"filter":"raw"}],"_links":{"self":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/posts\/16118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/users\/2140"}],"replies":[{"embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/comments?post=16118"}],"version-history":[{"count":0,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/posts\/16118\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/media?parent=16118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/categories?post=16118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/tags?post=16118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}